Full Process of Import Agency for US Originator Pharmaceuticals - Compliance Guide for Access Qualification, Customs Declaration & Inspection

Core Access Requirements for US Originator Pharmaceutical Import (2026 Edition)

In 2026,the General Administration of Customs and National Medical Products Administration have made partial adjustments to the supervision rules for imported originator pharmaceuticals.Besides conventional trade documents,two types of qualifications are mandatory for customs clearance: first,the Import Drug Registration Certificate issued by the National Medical Products Administration,which must cover the dosage form,specification,and manufacturer of the imported batch; second,the Import Drug Clearance Form issued by the medical products administration at the import port.For some rare disease drugs,a fast-track application is available,reducing the form issuance timeframe from 3 working days to 4 hours.

Accurate HS code classification is the foundation of all subsequent operations.Under the 2026 tariff adjustment plan,17 categories of anti-tumor and rare disease originator pharmaceuticals enjoy provisional zero-tariff treatment,while tariff rates for other categories range from 2% to 6%.When classifying,attention should be paid to distinguishing compound preparations with supporting drug delivery devices or accompanying test reagents,which cannot be directly categorized as ordinary pharmaceuticals.Otherwise,you may either overpay tariffs or trigger an audit due to missing declaration elements.

Common Pitfalls and Mitigation Solutions in Practical Operations

Last year,a pharmaceutical client from Jiangsu imported an anti-tumor originator pharmaceutical on its own.It declared a preparation with a dedicated pre-filled syringe as an ordinary oral preparation,omitting declaration elements for medical device accessories.The cargo was detained for 21 days at Shanghai Port,resulting in RMB 120,000 in demurrage and cold chain storage fees,and also triggered high-risk scrutiny for its next three import shipments.After engaging our services,we first assisted with pre-classification of the HS code,supplemented the application for 3C certification exemption for the drug delivery device,and resubmitted the declaration after adjusting the declaration elements.Now,the average customs clearance time for its cargo is 2 days,80% faster than before.

Core Pitfall Avoidance Checklist

• Conduct pre-review of import qualifications 30 days in advance to confirm the Import Drug Registration Certificate is valid,and the original factory inspection report and certificate of origin for the corresponding batch are complete
• Complete AMS and ISF 10+2 declarations 72 hours before shipment from the US,ensuring 100% consistency between manifest information,declaration elements and actual cargo to avoid return risks
• Conduct pre-review of customs valuation in advance,providing original factory invoices,foreign exchange payment vouchers and trade contracts as pricing basis to avoid clearance delays caused by price disputes
• Apply for customs green channel inspection in advance for cold-chain transported preparations,prioritizing sampling and testing to shorten cold chain storage duration and reduce the risk of drug deterioration

Core Risk Control and Service Advantages of Import Agency

In 2026,the US Department of Commerce added 23 categories of biological agents to the export control list for medical products.Originator pharmaceuticals involving gene therapy and cell therapy require advance application for US export licenses.Many customers are unaware of this rule,leading to cargo return due to missing certificates upon port arrival,with losses exceeding 40% of the cargo value.Our agency network in the US can assist in verifying the export control list in advance and handle relevant license applications to avoid return losses.

Headquartered in Shanghai,we support remote declaration at all national ports.Whether you import from Beijing,Guangzhou,Shenzhen,or Chengdu ports,you can coordinate with the same dedicated service team for unified handling,eliminating the need to engage different agents at different ports and reducing communication costs by 70%.For foreign exchange settlement,we offer exchange rate locking services to avoid losses from currency fluctuations.In 2025,we helped customers reduce total exchange losses by over RMB 12 million.

Two non-negotiable compliance red lines are defined here: First,it is strictly prohibited to evade tariffs by misdeclaring product names or underreporting prices.In 2026,the customs valuation system for medical products has been connected to a global pharmaceutical transaction price database.Underreporting prices will definitely trigger a price audit,resulting in supplementary tax payments with late fees at best,and inclusion in the dishonest enterprise list with all import and export operations under scrutiny at worst.Second,do not engage freight forwarders without pharmaceutical import agency qualifications.If cargo is detained due to incorrect document submission,the destruction cost exceeds 30% of the cargo value,leaving almost no room for recovery.

Import requirements vary significantly across different categories of originator pharmaceuticals.It is recommended to submit product information for free pre-review before import.We will customize an exclusive operation plan based on your product category,import port,and trade terms,clarifying the timeline and cost details for each step with no hidden charges.